NK-Cell Lymphoma, Unclassifiable
2 clinical trials · Condition
◉ Watch NK-Cell Lymphoma, Unclassifiable
| Record | Firm | Date |
|---|---|---|
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers (NCT02978625) | National Cancer Institute (NCI) | 2017-09-27 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (NCT03075553) | Mayo Clinic | 2017-05-17 |
Track NK-Cell Lymphoma, Unclassifiable automatically
Every clearance here is in the API, with alerts when new ones post.